Vamifeport | CAT#2095668-10-1 | ferroportin inhibitor

MedKoo Cat#: 462513 | Name: Vamifeport

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vamifeport is an oral ferroportin inhibitor designed to regulate iron homeostasis by blocking ferroportin-mediated iron export from cells, leading to reduced plasma iron levels. It has demonstrated bioactivity in preclinical and clinical studies for treating diseases associated with iron dysregulation, such as β-thalassemia and anemia of chronic disease. By targeting ferroportin, Vamifeport limits excessive iron availability, thereby reducing oxidative stress and improving erythropoiesis in iron-loading disorders.

Chemical Structure

Vamifeport

CAS#2095668-10-1 (free base)

Theoretical Analysis

MedKoo Cat#: 462513

Name: Vamifeport

CAS#: 2095668-10-1 (free base)

Chemical Formula: C21H21FN6O2

Exact Mass: 408.1710

Molecular Weight: 408.44

Elemental Analysis: C, 61.76; H, 5.18; F, 4.65; N, 20.58; O, 7.83

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 750.00	2 Weeks
10mg	USD 1,400.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

2095668-11-2 (HCl) 2095668-10-1 (free base)

Synonym

Vamifeport

IUPAC/Chemical Name

2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide

InChi Key

KNYVRFXIVWUGBZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H21FN6O2/c22-14-4-3-9-24-17(14)12-25-21(29)18-13-30-20(28-18)8-11-23-10-7-19-26-15-5-1-2-6-16(15)27-19/h1-6,9,13,23H,7-8,10-12H2,(H,25,29)(H,26,27)

SMILES Code

O=C(C1=COC(CCNCCC2=NC3=CC=CC=C3N2)=N1)NCC4=NC=CC=C4F

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 408.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mzembe G, Moya E, Mwangi MN, Ataide R, Harding R, Kaunda J, Zinenani T, Mhango G, Stones W, Mtambo O, Demir AY, Verhoef H, Braat S, Pasricha SR, Phiri KS. Postpartum maternal and infant haematological effects of second-trimester ferric carboxymaltose versus standard-of-care oral iron in Malawi: longitudinal follow-up of a randomised controlled trial. Lancet Glob Health. 2024 Dec;12(12):e2049-e2058. doi: 10.1016/S2214-109X(24)00380-2. PMID: 39577976; PMCID: PMC11584314. 2: Antypiuk A, Vance S, Sharma R, Passos ST, Asperti M, Navaneethabalakrishnan S, Durrenberger F, Manolova V, Vinchi F Prof. Genetic iron overload aggravates and pharmacological iron restriction improves MDS pathophysiology in a preclinical study. Blood. 2024 Oct 22:blood.2024026135. doi: 10.1182/blood.2024026135. Epub ahead of print. PMID: 39437711. 3: Pilo F, Angelucci E. Vamifeport: Monography of the First Oral Ferroportin Inhibitor. J Clin Med. 2024 Sep 18;13(18):5524. doi: 10.3390/jcm13185524. PMID: 39337010; PMCID: PMC11432582. 4: Nyffenegger N, Flace A, Varol A, Altermatt P, Doucerain C, Sundstrom H, Dürrenberger F, Manolova V. The oral ferroportin inhibitor vamifeport prevents liver iron overload in a mouse model of hemochromatosis. Hemasphere. 2024 Sep 12;8(9):e147. doi: 10.1002/hem3.147. PMID: 39267817; PMCID: PMC11391117. 5: Pasricha SR, Rogers L, Branca F, Garcia-Casal MN. Measuring haemoglobin concentration to define anaemia: WHO guidelines. Lancet. 2024 May 18;403(10440):1963-1966. doi: 10.1016/S0140-6736(24)00502-6. Epub 2024 Mar 14. PMID: 38493792. 6: Kalleda N, Flace A, Altermatt P, Ingoglia G, Doucerain C, Nyffenegger N, Dürrenberger F, Manolova V. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions. Haematologica. 2023 Oct 1;108(10):2703-2714. doi: 10.3324/haematol.2022.282328. PMID: 37165842; PMCID: PMC10543196. 7: Lehmann EF, Liziczai M, Drożdżyk K, Altermatt P, Langini C, Manolova V, Sundstrom H, Dürrenberger F, Dutzler R, Manatschal C. Structures of ferroportin in complex with its specific inhibitor vamifeport. Elife. 2023 Mar 21;12:e83053. doi: 10.7554/eLife.83053. PMID: 36943194; PMCID: PMC10030120. 8: Stetka J, Usart M, Kubovcakova L, Rai S, Rao TN, Sutter J, Hao-Shen H, Dirnhofer S, Geier F, Bader MS, Passweg JR, Manolova V, Dürrenberger F, Ahmed N, Schroeder T, Ganz T, Nemeth E, Silvestri L, Nai A, Camaschella C, Skoda RC. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood. 2023 Apr 27;141(17):2127-2140. doi: 10.1182/blood.2022017976. PMID: 36758212. 9: Nyffenegger N, Zennadi R, Kalleda N, Flace A, Ingoglia G, Buzzi RM, Doucerain C, Buehler PW, Schaer DJ, Dürrenberger F, Manolova V. The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease. Blood. 2022 Aug 18;140(7):769-781. doi: 10.1182/blood.2021014716. PMID: 35714304; PMCID: PMC9389634. 10: Porter J, Taher A, Viprakasit V, Kattamis A, Coates TD, Garbowski M, Dürrenberger F, Manolova V, Richard F, Cappellini MD. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development. Expert Rev Hematol. 2021 Jul;14(7):633-644. doi: 10.1080/17474086.2021.1935854. Epub 2021 Jul 29. PMID: 34324404.